StockNews.AI
MRK
StockNews.AI
4 hrs

FDA Approves Merck's KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)

1. FDA approves KEYTRUDA QLEX for subcutaneous use, expanding treatment options. 2. New formulation enhances administration efficiency and may boost MRK's market position.

FDA Approval
0%Current Return
VS
+0.01%S&P 500
$81.5109/19 05:42 PM EDTEvent Start
$81.5109/19 09:19 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The FDA approval of KEYTRUDA QLEX can lead to increased sales; similar past approvals spurred price growth.

How important is it?

The approval directly influences market perception and MRK's revenue potential in oncology.

Why Long Term?

Broader treatment options for cancer can support sustained growth and enhance market share over years.

Related Companies

ALTNNVSBMY
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for KEYTRUDA® (pembrolizumab). Berahyaluronidase alfa is a variant of human hyaluronidase developed and manufactured by Alteogen Inc. KEYTRUDA QLEX must be administer.

Related News